T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting

In conclusion, B7-H3Bi-Ab enhances the ability of T cells to kill hematologic tumor cells, and B7-H3 may serve as a novel target for immunotherapy against hematologic malignancy.

http://link.springer.com/10.1007/s10637-019-00819-y

Source: Investigational New Drugs - July 2, 2019 Category: Drugs & Pharmacology Source Type: research